December 30, 2013

Antibe Therapeutics Raises $899,445 in Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (December 30, 2013) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has closed its previously announced non-brokered private placement of units, … Continued

read
December 12, 2013

Antibe Therapeutics Announces Non-brokered Private Placement of up to $1,000,000

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO – (December 12, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces its intention to complete a non-brokered private placement of … Continued

read
November 7, 2013

Dr. John Wallace, Antibe Therapeutics Founder and Chief Science Officer, awarded the Heymans Foundation Memorial Medal

TORONTO, ONTARIO – (November 7, 2013) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is proud to announce that Dr. John Wallace, the Corporation’s Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today. This prestigious award, named after Corneille Heymans, a 1938 Nobel Prize winner for … Continued

read
October 4, 2013

Antibe Therapeutics Reports on Results of AGM Voting

TORONTO, ONTARIO – (October 4, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on September 30, 2013. The matters voted upon at the meeting and the results of the … Continued

read
August 30, 2013

Antibe Therapeutics Appoints New Chairman

TORONTO, ONTARIO – (August 30, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSX VENTURE: ATE) announced today that Walt Macnee has been appointed as Chairman of the Board of Directors of the Corporation to replace John Wallace, who will continue to serve as a director and Chief Science Officer. Mr. Macnee’s appointment was … Continued

read
August 22, 2013

Antibe Therapeutics Completes Final Tranche of IPO, bringing Total Raise to the Maximum Offering of $3,000,000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS TORONTO, ONTARIO – (August 22, 2013) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSX VENTURE: ATE) is pleased to announce that on August 22, 2013 … Continued

read

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK